The Anti-SARS-CoV-2 Effect and Mechanism of Chiehyuan Herbal Oral Protection Solution

Overview

Journal Heliyon

Specialty Social Sciences

Date 2023 Jul 24

PMID 37483781

Authors

Ching-Yuan Wu

Yao-Hsu Yang

Yu-Shih Lin

Li-Hsin Shu

Yu-Ching Cheng

Hung-Te Liu

Yin-Yin Lin

I-Yun Lee

Wei-Tai Shih

Pei-Rung Yang

Ying-Ying Tsai

Geng-He Chang

Cheng-Ming Hsu

Reming-Albert Yeh

Yu-Huei Wu

Yu-Heng Wu

Rou-Chen Shen

Ming-Shao Tsai

Affiliations

Soon will be listed here.

Abstract

The Chiehyuan herbal oral protection solution (GB-2) is a herbal mixture commonly utilized in Taiwan for combating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as per traditional Chinese medicine practices. This study assessed the clinical impact of GB-2 through prospective clinical trials. With twice-daily use for a week, GB-2 was shown to diminish the expression of angiotensin-converting enzyme 2 (ACE2) in oral mucosal cells. Moreover, after two weeks of use, it could reduce transmembrane protease, serine 2 (TMRPSS2) expression in these cells. Additionally, in vitro experiments demonstrated that GB-2 lessened the entry efficiency of the Omicron, L452R-D614G, T478K-D614G, and L452R-T478K-D614G variants of the SARS-CoV-2 pseudotyped lentivirus. It also impeded the interaction between ACE2 and the receptor-binding domain (RBD) presenting N501Y-K417N-E484A-G339D-Q493R-G496S-Q498R and L452R-T478K mutations. Glycyrrhizic acid, a major compound in GB-2, also hindered the entry of the Omicron variant (BA.1) of the SARS-CoV-2 pseudotyped lentivirus by obstructing the binding between ACE2 and the RBD presenting the N501Y-K417N-E484A-G339D-Q493R-G496S-Q498R mutation. To sum up, these findings suggest that GB-2 can decrease ACE2 and TMPRSS2 expression in oral mucosal cells. Both glycyrrhizic acid and GB-2 were found to reduce the entry efficiency of the Omicron variant (BA.1) of the SARS-CoV-2 pseudotyped lentivirus and block the binding between ACE2 and the RBD with the N501Y-K417N-E484A-G339D-Q493R-G496S-Q498R mutation. This evidence implies that GB-2 might be a potential candidate for further study as a preventative measure against SARS-CoV-2 infection.

Citing Articles

The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants.

Lu C, Lung J, Shu L, Liu H, Wu Y, Lin Y Int J Mol Sci. 2024; 25(17).

PMID: 39273444 PMC: 11394907. DOI: 10.3390/ijms25179498.

SARS-CoV-2 mechanisms of cell tropism in various organs considering host factors.

Behboudi E, Nooreddin Faraji S, Daryabor G, Hashemi S, Asadi M, Edalat F Heliyon. 2024; 10(4):e26577.

PMID: 38420467 PMC: 10901034. DOI: 10.1016/j.heliyon.2024.e26577.

References

Pompei R, Flore O, Marccialis M, Pani A, LODDO B . Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature. 1979; 281(5733):689-90. DOI: 10.1038/281689a0. View

Liu Z, VanBlargan L, Bloyet L, Rothlauf P, Chen R, Stumpf S . Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021; 29(3):477-488.e4. PMC: 7839837. DOI: 10.1016/j.chom.2021.01.014. View

Garcia-Sanchez A, Pena-Cardelles J, Ruiz S, Robles F, Ordonez-Fernandez E, Salgado-Peralvo A . Efficacy of Pre-Procedural Mouthwashes against SARS-CoV-2: A Systematic Review of Randomized Controlled Trials. J Clin Med. 2022; 11(6). PMC: 8955331. DOI: 10.3390/jcm11061692. View

Ohgitani E, Shin-Ya M, Ichitani M, Kobayashi M, Takihara T, Kawamoto M . Significant Inactivation of SARS-CoV-2 In Vitro by a Green Tea Catechin, a Catechin-Derivative, and Black Tea Galloylated Theaflavins. Molecules. 2021; 26(12). PMC: 8230566. DOI: 10.3390/molecules26123572. View

Chavda V, Patel A, Vihol D, Vaghasiya D, Ahmed K, Trivedi K . Herbal Remedies, Nutraceuticals, and Dietary Supplements for COVID-19 Management: An Update. Clin Complement Med Pharmacol. 2023; 2(1):100021. PMC: 8816850. DOI: 10.1016/j.ccmp.2022.100021. View

Li J, Xu D, Wang L, Zhang M, Zhang G, Li E . Glycyrrhizic Acid Inhibits SARS-CoV-2 Infection by Blocking Spike Protein-Mediated Cell Attachment. Molecules. 2021; 26(20). PMC: 8539771. DOI: 10.3390/molecules26206090. View

Lung J, Lin Y, Yang Y, Chou Y, Shu L, Cheng Y . The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase. J Med Virol. 2020; 92(6):693-697. PMC: 7228302. DOI: 10.1002/jmv.25761. View

Chan K, Dorosky D, Sharma P, Abbasi S, Dye J, Kranz D . Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 2020; 369(6508):1261-1265. PMC: 7574912. DOI: 10.1126/science.abc0870. View

Adhikari P, Jawad B, Podgornik R, Ching W . Mutations of Omicron Variant at the Interface of the Receptor Domain Motif and Human Angiotensin-Converting Enzyme-2. Int J Mol Sci. 2022; 23(5). PMC: 8911136. DOI: 10.3390/ijms23052870. View

10.

Starr T, Greaney A, Addetia A, Hannon W, Choudhary M, Dingens A . Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021; 371(6531):850-854. PMC: 7963219. DOI: 10.1126/science.abf9302. View

11.

Vardhan S, Sahoo S . Computational studies on the interaction of SARS-CoV-2 Omicron SGp RBD with human receptor ACE2, limonin and glycyrrhizic acid. Comput Biol Med. 2022; 144:105367. PMC: 8886687. DOI: 10.1016/j.compbiomed.2022.105367. View

12.

Deng X, Garcia-Knight M, Khalid M, Servellita V, Wang C, Morris M . Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021; 184(13):3426-3437.e8. PMC: 8057738. DOI: 10.1016/j.cell.2021.04.025. View

13.

McCallum M, Bassi J, De Marco A, Chen A, Walls A, di Iulio J . SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science. 2021; 373(6555):648-654. PMC: 9835956. DOI: 10.1126/science.abi7994. View

14.

Eduardo F, Correa L, Heller D, Daep C, Benitez C, Malheiros Z . Salivary SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial. Heliyon. 2021; 7(6):e07346. PMC: 8222261. DOI: 10.1016/j.heliyon.2021.e07346. View

15.

Hoffmann M, Kleine-Weber H, Pohlmann S . A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020; 78(4):779-784.e5. PMC: 7194065. DOI: 10.1016/j.molcel.2020.04.022. View

16.

Morawska L, Milton D . It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2020; 71(9):2311-2313. PMC: 7454469. DOI: 10.1093/cid/ciaa939. View

17.

Kumar S, Thambiraja T, Karuppanan K, Subramaniam G . Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol. 2021; 94(4):1641-1649. DOI: 10.1002/jmv.27526. View

18.

Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V . Analysis of the Delta Variant B.1.617.2 COVID-19. Clin Pract. 2021; 11(4):778-784. PMC: 8544471. DOI: 10.3390/clinpract11040093. View

19.

Theda C, Hwang S, Czajko A, Loke Y, Leong P, Craig J . Quantitation of the cellular content of saliva and buccal swab samples. Sci Rep. 2018; 8(1):6944. PMC: 5932057. DOI: 10.1038/s41598-018-25311-0. View

20.

Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B . Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020; 12(1):9. PMC: 7054527. DOI: 10.1038/s41368-020-0075-9. View